The involvement of advanced glycation endproducts (AGEs) in renal injury of diabetic glomerulosclerosis: association with phenotypic change in renal cells and infiltration of immune cells.
BACKGROUND
Glycation of proteins is regarded as one of the major causes of the progression of diabetic nephropathy (DN) and of the phenotypic changes in glomerular mesangial cells (MC) and the cellular infiltration that occurs in MC from DN. It thus is very important to study the interrelationships and interaction between these causes.


METHODS
The localization of advanced glycation endproducts (AGEs), cytoskeletal proteins, and immune cell infiltration was evaluated by immunohistochemical study in patients with DN.


RESULTS
N(Epsilon)-(carboxymethyl)lysine (CML), Alpha-smooth muscle actin (SMA), and low-molecular-weight caldesmon (L-CLD) were localized in the mesangial area in DN. The intensity of mesangial SMA and L-CLD expression was significantly correlated with the index of diabetic glomerulosclerosis (IDGS), while the expression of pentosidine was correlated with the IDGS and with 24-h urinary protein. Pentosidine was localized in glomerular basement membrane (GBM) only in DN and had a significant correlation with the mesangial expression of SMA and L-CLD. Pyrraline deposition on the tubular basement membrane, and the expression of SMA and L-CLD, and the infiltration of immune cells were observed in interstitial areas in DN. The intensity of L-CLD expression had a close relationship with pyrraline deposition and immune cell infiltration. The expression of SMA and L-CLD in interstitial areas was significantly correlated with the percent interstitial volume.


CONCLUSIONS
AGEs are involved in renal injury in DN, and their effect is, at least in part, exercised via phenotypic changes in intrinsic renal cells and by the infiltration of immune cells.
Mao
Yonghui
Y
Department of Nephrology of Beijing Hospital, Beijing, China.
Ootaka
Tetsuya
T
Saito
Takao
T
Sato
Hiroshi
H
Sato
Toshinobu
T
Ito
Sadayoshi
S
D000199:Actins / Q000276:immunology / Q000378:metabolism; D002148:Calmodulin-Binding Proteins / Q000276:immunology / Q000378:metabolism; D003599:Cytoskeleton / Q000378:metabolism; D003928:Diabetic Nephropathies / Q000276:immunology / Q000378:metabolism* / Q000473:pathology*; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans; D007124:Immunoenzyme Techniques; D007962:Leukocytes / Q000473:pathology*; D008875:Middle Aged; D010641:Phenotype
D000199:Actins; D002148:Calmodulin-Binding Proteins; D017127:Glycation End Products, Advanced